Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Optical Imaging | 2 | 2017 | 52 | 0.530 |
Why?
|
Positron-Emission Tomography | 5 | 2018 | 341 | 0.500 |
Why?
|
Implants, Experimental | 1 | 2013 | 16 | 0.410 |
Why?
|
Peritoneum | 1 | 2013 | 57 | 0.400 |
Why?
|
Luminescent Measurements | 1 | 2013 | 62 | 0.400 |
Why?
|
Molecular Imaging | 1 | 2013 | 70 | 0.380 |
Why?
|
Nanoparticles | 5 | 2017 | 168 | 0.350 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2013 | 142 | 0.270 |
Why?
|
Image Enhancement | 2 | 2007 | 562 | 0.230 |
Why?
|
Transducers | 1 | 2004 | 42 | 0.220 |
Why?
|
Neural Stem Cells | 2 | 2015 | 60 | 0.220 |
Why?
|
Silicon Dioxide | 2 | 2017 | 37 | 0.220 |
Why?
|
Glioblastoma | 2 | 2015 | 274 | 0.190 |
Why?
|
Imaging, Three-Dimensional | 1 | 2004 | 608 | 0.170 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2004 | 693 | 0.160 |
Why?
|
Brain Neoplasms | 2 | 2015 | 800 | 0.150 |
Why?
|
Hypertension, Pulmonary | 2 | 2013 | 376 | 0.150 |
Why?
|
4-Aminopyridine | 1 | 2018 | 37 | 0.140 |
Why?
|
Fluorine Radioisotopes | 1 | 2018 | 25 | 0.140 |
Why?
|
Demyelinating Diseases | 1 | 2018 | 50 | 0.140 |
Why?
|
Luminescence | 1 | 2017 | 20 | 0.140 |
Why?
|
Algorithms | 2 | 2007 | 1956 | 0.130 |
Why?
|
Lectins | 1 | 2017 | 86 | 0.130 |
Why?
|
Mice, Nude | 3 | 2015 | 828 | 0.130 |
Why?
|
Mice | 10 | 2018 | 12110 | 0.130 |
Why?
|
Colonic Polyps | 1 | 2017 | 134 | 0.120 |
Why?
|
Lung Neoplasms | 3 | 2015 | 2394 | 0.120 |
Why?
|
Potassium Channels | 1 | 2018 | 347 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2017 | 201 | 0.120 |
Why?
|
Materials Testing | 2 | 2013 | 94 | 0.120 |
Why?
|
Fractals | 1 | 2015 | 42 | 0.120 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 96 | 0.120 |
Why?
|
Cell Line, Tumor | 4 | 2015 | 2669 | 0.120 |
Why?
|
Multimodal Imaging | 2 | 2015 | 115 | 0.120 |
Why?
|
Phantoms, Imaging | 4 | 2017 | 474 | 0.110 |
Why?
|
Chelating Agents | 1 | 2013 | 68 | 0.100 |
Why?
|
Endoscopy | 1 | 2017 | 363 | 0.100 |
Why?
|
Polyvinyl Chloride | 1 | 2013 | 7 | 0.100 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 76 | 0.100 |
Why?
|
Mitochondrial Dynamics | 1 | 2013 | 56 | 0.100 |
Why?
|
Organometallic Compounds | 1 | 2013 | 142 | 0.100 |
Why?
|
Animals | 12 | 2018 | 28003 | 0.100 |
Why?
|
Abdomen | 1 | 2013 | 125 | 0.100 |
Why?
|
Mitochondrial Proteins | 1 | 2013 | 129 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1138 | 0.100 |
Why?
|
Heat-Shock Proteins | 1 | 2013 | 183 | 0.100 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2012 | 121 | 0.090 |
Why?
|
Disease Models, Animal | 3 | 2013 | 2448 | 0.090 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2010 | 24 | 0.090 |
Why?
|
Receptors, Opioid, mu | 1 | 2010 | 45 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 866 | 0.090 |
Why?
|
Monitoring, Physiologic | 1 | 2012 | 267 | 0.080 |
Why?
|
Tumor Burden | 1 | 2011 | 314 | 0.080 |
Why?
|
Lung Injury | 1 | 2010 | 57 | 0.080 |
Why?
|
Simvastatin | 1 | 2010 | 106 | 0.080 |
Why?
|
Disease Progression | 2 | 2012 | 1503 | 0.080 |
Why?
|
Drug Carriers | 1 | 2010 | 82 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2010 | 158 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 1271 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 1045 | 0.070 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2007 | 8 | 0.070 |
Why?
|
Lung | 2 | 2013 | 1337 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 391 | 0.060 |
Why?
|
Liver | 1 | 2010 | 1228 | 0.060 |
Why?
|
Transcription Factors | 1 | 2013 | 1684 | 0.060 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2004 | 33 | 0.060 |
Why?
|
Equipment Failure Analysis | 1 | 2004 | 88 | 0.060 |
Why?
|
Fourier Analysis | 1 | 2004 | 128 | 0.060 |
Why?
|
Rats | 3 | 2018 | 4067 | 0.050 |
Why?
|
Information Storage and Retrieval | 1 | 2004 | 123 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2017 | 1052 | 0.050 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2004 | 203 | 0.050 |
Why?
|
Equipment Design | 1 | 2004 | 418 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2012 | 2794 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2015 | 193 | 0.050 |
Why?
|
Humans | 11 | 2018 | 92337 | 0.050 |
Why?
|
Familial Primary Pulmonary Hypertension | 2 | 2013 | 65 | 0.050 |
Why?
|
Fluorescent Dyes | 2 | 2017 | 260 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 2004 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 2680 | 0.050 |
Why?
|
Female | 6 | 2018 | 47893 | 0.040 |
Why?
|
Drug Delivery Systems | 2 | 2013 | 183 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 2009 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2013 | 1235 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2013 | 3053 | 0.040 |
Why?
|
Radioactive Tracers | 1 | 2018 | 6 | 0.040 |
Why?
|
Calibration | 1 | 2017 | 103 | 0.030 |
Why?
|
Mice, Inbred A | 1 | 2017 | 23 | 0.030 |
Why?
|
X-Rays | 1 | 2017 | 138 | 0.030 |
Why?
|
Signal-To-Noise Ratio | 1 | 2017 | 109 | 0.030 |
Why?
|
Apoptosis | 2 | 2013 | 1743 | 0.030 |
Why?
|
Indium Radioisotopes | 1 | 2015 | 10 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2015 | 52 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2015 | 295 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2018 | 468 | 0.030 |
Why?
|
Colonoscopy | 1 | 2017 | 300 | 0.030 |
Why?
|
Colon | 1 | 2017 | 527 | 0.030 |
Why?
|
Nanomedicine | 1 | 2013 | 14 | 0.030 |
Why?
|
Optic Atrophy, Autosomal Dominant | 1 | 2013 | 4 | 0.030 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 18 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2013 | 137 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2010 | 3360 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2013 | 56 | 0.030 |
Why?
|
Mice, SCID | 1 | 2013 | 265 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 398 | 0.030 |
Why?
|
Lysosomes | 1 | 2013 | 117 | 0.020 |
Why?
|
Doxorubicin | 1 | 2013 | 296 | 0.020 |
Why?
|
Cell Death | 1 | 2013 | 261 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 141 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 501 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 441 | 0.020 |
Why?
|
Male | 4 | 2018 | 43925 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 2012 | 251 | 0.020 |
Why?
|
Biological Transport | 1 | 2011 | 410 | 0.020 |
Why?
|
Bronchoalveolar Lavage | 1 | 2010 | 27 | 0.020 |
Why?
|
Hyaluronan Receptors | 1 | 2010 | 38 | 0.020 |
Why?
|
Radiation Pneumonitis | 1 | 2010 | 23 | 0.020 |
Why?
|
Indocyanine Green | 1 | 2010 | 24 | 0.020 |
Why?
|
Coloring Agents | 1 | 2010 | 65 | 0.020 |
Why?
|
Surface Properties | 1 | 2010 | 131 | 0.020 |
Why?
|
Protein Interaction Mapping | 1 | 2010 | 81 | 0.020 |
Why?
|
Cell Movement | 1 | 2013 | 797 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 1939 | 0.020 |
Why?
|
Molecular Structure | 1 | 2010 | 307 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2010 | 502 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2010 | 569 | 0.020 |
Why?
|
Models, Biological | 1 | 2015 | 1786 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 1150 | 0.020 |
Why?
|
Polymethyl Methacrylate | 1 | 2007 | 15 | 0.020 |
Why?
|
Fibrosarcoma | 1 | 2007 | 87 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2011 | 1071 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2013 | 1720 | 0.020 |
Why?
|
Osteosarcoma | 1 | 2007 | 159 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2013 | 1240 | 0.020 |
Why?
|
Extremities | 1 | 2007 | 177 | 0.020 |
Why?
|
Cell Line | 1 | 2010 | 2505 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2011 | 2035 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2010 | 2087 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2010 | 1163 | 0.020 |
Why?
|
Prognosis | 1 | 2011 | 3872 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 3509 | 0.010 |
Why?
|
Time Factors | 1 | 2011 | 5430 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2011 | 9703 | 0.010 |
Why?
|
Aged | 1 | 2011 | 19943 | 0.010 |
Why?
|